Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study.

While this difference did not reach statistical significance, it is consistent with the results of prospective trials in which ribociclib demonstrated consistent improvements in OS, both in combination with fulvestrant in the MONALEESA-3 trial and with letrozole in MONALEESA-2, whereas palbociclib conferred only a non significant OS improvement in both PALOMA-3 and PALOMA-2 [ 23 ].

also in 111,027 other papers